Mostrar o rexistro simple do ítem
Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)
dc.contributor.author | Zapata-Arriaza, Elena | |
dc.contributor.author | Medina-Rodríguez, Manuel | |
dc.contributor.author | Moniche Álvarez, Francisco | |
dc.contributor.author | Albóniga‑Chindurza, Asier de | |
dc.contributor.author | Aguilar-Pérez, Marta | |
dc.contributor.author | Ainz-Gómez, Leire | |
dc.contributor.author | Baena-Palomino, Pablo | |
dc.contributor.author | Zamora, Aynara | |
dc.contributor.author | Pardo-Galiana, Blanca | |
dc.contributor.author | Delgado-Acosta, Fernando | |
dc.contributor.author | Valverde Moyano, Roberto | |
dc.contributor.author | Jiménez-Gómez, Elvira | |
dc.contributor.author | Bravo Rey, Isabel | |
dc.contributor.author | Oteros Fernández, Rafael | |
dc.contributor.author | Escudero-Martínez, Irene | |
dc.contributor.author | Vielba-Gómez, Isabel | |
dc.contributor.author | Morales Caba, Lluis | |
dc.contributor.author | Díaz Pérez, José | |
dc.contributor.author | García Molina, Estefanía | |
dc.contributor.author | Mosteiro, Sonia | |
dc.contributor.author | Castellanos, María del Mar | |
dc.contributor.author | Amaya Pascasio, Laura | |
dc.contributor.author | Hidalgo, Carlos | |
dc.contributor.author | Freijo Guerrero, María del Mar | |
dc.contributor.author | González-Díaz, Eva | |
dc.contributor.author | Ramírez Moreno, José María | |
dc.contributor.author | Fernández Prudencio, Luis | |
dc.contributor.author | Terceño Izaga, Mikel | |
dc.contributor.author | Bashir Viturro, Saima | |
dc.contributor.author | Gamero-García, Miguel-Ángel | |
dc.contributor.author | Jiménez Jorge, Silvia | |
dc.contributor.author | Rosso Fernández, Clara | |
dc.contributor.author | Montaner, Joan | |
dc.contributor.author | González García, Alejandro | |
dc.date.accessioned | 2024-06-20T10:20:27Z | |
dc.date.available | 2024-06-20T10:20:27Z | |
dc.date.issued | 2024-01-09 | |
dc.identifier.citation | Zapata-Arriaza E, Medina-Rodríguez M, Moniche Álvarez F, de Albóniga-Chindurza A, Aguilar-Pérez M, Ainz-Gómez L, Baena-Palomino P, Zamora A, Pardo-Galiana B, Delgado-Acosta F, Valverde Moyano R, Jiménez-Gómez E, Bravo Rey I, Oteros Fernández R, Escudero-Martínez I, Vielba-Gomez I, Morales Caba L, Díaz Pérez J, García Molina E, Mosteiro S, Castellanos Rodrigo MDM, Amaya Pascasio L, Hidalgo C, Freijo Guerrero MDM, González Díaz E, Ramírez Moreno JM, Fernández Prudencio L, Terceño Izaga M, Bashir Viturro S, Gamero-García MÁ, Jiménez Jorge S, Rosso Fernández C, Montaner J, González García A. Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial). Trials. 2024 Jan 9;25(1):35. | es_ES |
dc.identifier.issn | 1745-6215 | |
dc.identifier.uri | http://hdl.handle.net/2183/37205 | |
dc.description | Study protocol | es_ES |
dc.description.abstract | [Abstract] Rationale: In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients to avoid in-stent reocclusion is yet to be elucidated. Aims: To assess efficacy and safety of intravenous tirofiban versus intravenous aspirin in patients undergoing MT plus carotid stenting in the setting of AIS due to TL. Sample size estimates: Two hundred forty patients will be enrolled, 120 in every treatment arm. Methods and design: A multicenter, prospective, randomized, controlled (aspirin group), assessor-blinded clinical trial will be conducted. Patients fulfilling the inclusion criteria will be randomized at MT onset to the experimental or control group (1:1). Intravenous aspirin will be administered at a 500-mg single dose and tirofiban at a 500-mcg bolus followed by a 200-mcg/h infusion during the first 24 h. All patients will be followed for up to 3 months. Study outcomes: Primary efficacy outcome will be the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. Primary safety outcome will be the rate of symptomatic intracranial hemorrhage. Discussion: This will be the first clinical trial to assess the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL. | es_ES |
dc.description.sponsorship | This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReNCode: 21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015). | es_ES |
dc.description.sponsorship | info:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI21%2F01322/ES/PROYECTO ATILA: ASPIRINA VS TIROFIBAN EN EL TRATAMIENTO ENDOVASCULAR PARA PACIENTES CON ICTUS ISQUEMICO AGUDO POR LESION EN TANDEM | es_ES |
dc.description.sponsorship | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/RD16%2F0019%2F0015/ES/Red de Enfermedades Vasculares Cerebrales. INVICTUS PLUS | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Nature | es_ES |
dc.relation.uri | https://doi.org/10.1186/s13063-023-07817-9 | es_ES |
dc.rights | Creative Commons Attribution 4.0 International License (CC-BY 4.0) | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Antiplatelet therapy | es_ES |
dc.subject | Protocol | es_ES |
dc.subject | Statistics | es_ES |
dc.subject | Stroke | es_ES |
dc.subject | Tandem occlusion | es_ES |
dc.title | Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Trials | es_ES |
UDC.volume | 25 | es_ES |
UDC.startPage | 35 | es_ES |
dc.identifier.doi | 10.1186/s13063-023-07817-9 |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-EC-Artigos [25]